A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.
Kobayashi T, et al. Among authors: koizumi t.
Cancer Chemother Pharmacol. 2012 May;69(5):1241-6. doi: 10.1007/s00280-012-1831-0. Epub 2012 Jan 26.
Cancer Chemother Pharmacol. 2012.
PMID: 22278730
Clinical Trial.